Managing Hyperphosphatemia in CKD: Current Insights into Pathophysiology and Therapeutic Approaches

Chronic Kidney Disease (CKD) is a progressive condition marked by a gradual loss of renal function and commonly associated with disturbances in mineral metabolism, particularly phosphate. As kidney function declines, phosphate homeostasis becomes impaired, leading to hyperphosphatemia, secondary hyperparathyroidism, and increased cardiovascular risks. This review explores the pathophysiological changes in phosphate metabolism in CKD, focusing on hormonal regulation involving parathyroid hormone (PTH), vitamin D, and fibroblast growth factor 23 (FGF23), as well as the roles of αKlotho and NaPi co-transporters. The paper outlines the normal mechanisms of phosphate balance, factors contributing to dysregulation in CKD, and associated complications such as bone disease and vascular calcification. Additionally, the review provides an in-depth analysis of therapeutic strategies, including dietary phosphate restriction, dialysis modification, and phosphate binders like Sevelamer and calcium acetate. Advantages, limitations, side effects, and pharmacodynamic profiles of these agents are discussed in detail. Special emphasis is given to patient education, lifestyle interventions, and pharmacologic treatment to manage hyperphosphatemia effectively. The importance of early diagnosis, screening of high-risk populations, and regular monitoring of phosphorus levels is also highlighted. In conclusion, optimizing phosphate control is crucial in delaying CKD progression, minimizing systemic complications, and improving quality of life. A multidisciplinary approach involving nephrologists, dietitians, and patient participation is essential for effective CKD management.